Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in ...

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

OpenAI claims supremacy across coding, agentic skills and nuanced context, to name a a few. Perhaps ironic in this moment, a mistake in accuracy graphs during the official presentation ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...